Originally published by our sister publication Clinical Oncology News
By David Wild
Vedolizumab (Entyvio, Millennium Pharmaceuticals), a drug used frequently for inflammatory bowel disease, improves outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematologic malignancies, according to the phase 3 GRAPHITE trial. The study demonstrated that the gut-selective anti-lymphocyte trafficking humanized monoclonal antibody reduced the incidence of